Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026)
Purple Biotech (PPBT) reported Income from Continuing Operations of 2200000.0 for Q1 2026, up 67.05% year-over-year from 1317000.0 in Q1 2025, and down 90.35% quarter-over-quarter from 22808000.0 in Q4 2025.
Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 13 years of Income from Continuing Operations data on file, last reported at 2200000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 2200000.0, up 67.05% year-over-year; the trailing twelve-month figure through Mar 2026 was 27292000.0 (up 362.89% YoY), and the FY2025 annual result was 26052000.0, up 169.86% from the prior year.
- Income from Continuing Operations fell to 2200000.0 in Q1 2026 per PPBT's latest filing, from 22808000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 22808000.0 in Q4 2025 and troughed at 217000.0 in Q4 2024.
- A 5-year average of 4510058.82 and a median of 4304000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 93.19% in 2024, then soared 10410.6% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 5740000.0 in 2022, then tumbled by 44.49% to 3186000.0 in 2023, then plunged by 93.19% to 217000.0 in 2024, then soared by 10410.6% to 22808000.0 in 2025, then sank by 90.35% to 2200000.0 in 2026.
- Business Quant data shows PPBT's Income from Continuing Operations at 2200000.0 in Q1 2026, 22808000.0 in Q4 2025, and 1134000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 217,000.00 |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 4.62 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 5.74 Mn |
| Sep 30, 2022 | 4.67 Mn |
| Jun 30, 2022 | 4.30 Mn |
| Mar 31, 2022 | 7.23 Mn |
| Dec 31, 2021 | 4.35 Mn |
| Sep 30, 2021 | 3.64 Mn |
| Jun 30, 2021 | 3.32 Mn |